Positive News Sentiment NASDAQ:DMAC DiaMedica Therapeutics Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding DiaMedica Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $2.07 +0.05 (+2.48%) (As of 07/1/2022 12:00 AM ET) Add Compare Share Today's Range$1.99▼$2.1050-Day Range$1.86▼$2.6252-Week Range$1.62▼$4.82Volume23,266 shsAverage Volume59,797 shsMarket Capitalization$54.74 millionP/E RatioN/ADividend YieldN/APrice Target$24.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media DiaMedica Therapeutics Stock Forecast (MarketRank)Analyst RatingBuy3.00 Rating ScoreUpside/Downside1,059.4% Upside$24.00 Price TargetShort InterestHealthy0.29% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.1.82 out of 5 starsMedical Sector722nd out of 1,428 stocksPharmaceutical Preparations Industry355th out of 682 stocks 3.5 Analyst's Opinion Consensus RatingDiaMedica Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $24.00, DiaMedica Therapeutics has a forecasted upside of 1,059.4% from its current price of $2.07.Amount of Analyst CoverageDiaMedica Therapeutics has received no research coverage in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted0.29% of the float of DiaMedica Therapeutics has been sold short.Short Interest Ratio / Days to CoverDiaMedica Therapeutics has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in DiaMedica Therapeutics has recently decreased by 1.57%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldDiaMedica Therapeutics does not currently pay a dividend.Dividend GrowthDiaMedica Therapeutics does not have a long track record of dividend growth. Previous Next 0.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for DMAC. Previous Next 3.8 News and Social Media Coverage News SentimentDiaMedica Therapeutics has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.77 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for DiaMedica Therapeutics this week, compared to 0 articles on an average week.Search InterestOnly 3 people have searched for DMAC on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows2 people have added DiaMedica Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, DiaMedica Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.60% of the stock of DiaMedica Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 19.16% of the stock of DiaMedica Therapeutics is held by institutions. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of DiaMedica Therapeutics is -3.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of DiaMedica Therapeutics is -3.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDiaMedica Therapeutics has a P/B Ratio of 1.24. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive DMAC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for DiaMedica Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address About DiaMedica Therapeutics (NASDAQ:DMAC)DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.Read More DMAC Stock News HeadlinesJune 12, 2022 | americanbankingnews.comDiaMedica Therapeutics Inc. (NASDAQ:DMAC) Sees Significant Decrease in Short InterestJune 9, 2022 | americanbankingnews.comFinancial Analysis: Nanobiotix (NASDAQ:NBTX) vs. DiaMedica Therapeutics (NASDAQ:DMAC)May 25, 2022 | finance.yahoo.comDiaMedica Therapeutics to Attend the 19th Annual Craig-Hallum Institutional Investor Conference Wednesday, June 1, 2022May 7, 2022 | finance.yahoo.comRecent gains in DiaMedica Therapeutics Inc. (NASDAQ:DMAC) help add back some value on insider purchases worth US$630k, still down US$149kMay 4, 2022 | seekingalpha.comDiaMedica Therapeutics GAAP EPS of -$0.13 beats by $0.07May 4, 2022 | finance.yahoo.comDiaMedica Therapeutics Provides a Business Update and Announces First Quarter 2022 Financial ResultsApril 28, 2022 | finance.yahoo.comDiaMedica Therapeutics to Report First Quarter 2022 Financial Results and Provide a Business Update May 5, 2022March 14, 2022 | seekingalpha.comDiaMedica Therapeutics GAAP EPS of -$0.65 beats by $0.08March 14, 2022 | finance.yahoo.comDiaMedica Therapeutics Provides a Business Update and Announces Fourth Quarter 2021 Financial ResultsMarch 8, 2022 | finance.yahoo.comDiaMedica Therapeutics to Report Fourth Quarter 2021 Financial Results and Provide a Business Update March 15, 2022February 4, 2022 | finance.yahoo.comDiaMedica Therapeutics (NASDAQ:DMAC) Is In A Good Position To Deliver On Growth PlansFebruary 2, 2022 | finance.yahoo.comDiaMedica Therapeutics Announces Appointment of Dominic Cundari as Chief Commercial OfficerJanuary 25, 2022 | finance.yahoo.comDiaMedica Therapeutics to Present Research at International Stroke ConferenceJanuary 20, 2022 | nasdaq.comDiaMedica Therapeutics Inc. Common Stock (DMAC)January 5, 2022 | seekingalpha.comDiaMedica Therapeutics appoints chief medical officerJanuary 5, 2022 | finance.yahoo.comDiaMedica Therapeutics Appoints Dr. Kirsten Gruis as Chief Medical OfficerDecember 13, 2021 | finance.yahoo.comDiaMedica Therapeutics Announces Participation in LifeSci Partners 11th Annual Corporate Access EventNovember 17, 2021 | finance.yahoo.comDiaMedica Therapeutics to Present at the Piper Sandler 33rd Annual Virtual Healthcare ConferenceNovember 10, 2021 | finance.yahoo.comDiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2021 Financial ResultsNovember 9, 2021 | finance.yahoo.comDiaMedica Therapeutics to Attend the 12th Annual Craig-Hallum Alpha Select Conference November 16, 2021November 8, 2021 | finance.yahoo.comDiaMedica Therapeutics Announces Addition of Stroke Recurrence as a Second Independent Primary Endpoint in ReMEDy2 Phase 2/3 AIS TrialNovember 4, 2021 | finance.yahoo.comDiaMedica Therapeutics to Report Third Quarter 2021 Financial Results and Provide a Business Update November 11, 2021October 18, 2021 | finance.yahoo.comDiaMedica Therapeutics Announces Late Breaking Data from REDUX Phase 2 Trial to be Presented at ASN Kidney Week 2021October 9, 2021 | nasdaq.comGreat news for DiaMedica Therapeutics Inc. (NASDAQ:DMAC): Insiders acquired stock in large numbers last yearOctober 8, 2021 | finance.yahoo.comQuite a few insiders invested in DiaMedica Therapeutics Inc. (NASDAQ:DMAC) last year which is positive news for shareholdersSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:DMAC CUSIPN/A CIK1401040 Webwww.diamedica.com Phone(763) 312-6755FaxN/AEmployees14Year FoundedN/ACompany Calendar Last Earnings5/04/2022Today7/02/2022Next Earnings (Estimated)8/10/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$24.00 High Stock Price Forecast$24.00 Low Stock Price Forecast$24.00 Forecasted Upside/Downside+1,059.4%Consensus RatingBuy Rating Score (0-4)3 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.58) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-13.59 million Net MarginsN/A Pretax MarginN/A Return on Equity-35.43% Return on Assets-34.08% Debt Debt-to-Equity RatioN/A Current Ratio29.37 Quick Ratio29.37 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.67 per share Price / Book1.24Miscellaneous Outstanding Shares26,443,000Free Float24,962,000Market Cap$54.74 million OptionableNot Optionable Beta2.30 DiaMedica Therapeutics Frequently Asked Questions Should I buy or sell DiaMedica Therapeutics stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DiaMedica Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" DiaMedica Therapeutics stock. View analyst ratings for DiaMedica Therapeutics or view top-rated stocks. What is DiaMedica Therapeutics' stock price forecast for 2022? 1 brokerages have issued twelve-month price targets for DiaMedica Therapeutics' shares. Their DMAC stock forecasts range from $24.00 to $24.00. On average, they predict DiaMedica Therapeutics' share price to reach $24.00 in the next twelve months. This suggests a possible upside of 1,059.4% from the stock's current price. View analysts' price targets for DiaMedica Therapeutics or view top-rated stocks among Wall Street analysts. How has DiaMedica Therapeutics' stock performed in 2022? DiaMedica Therapeutics' stock was trading at $3.73 at the beginning of 2022. Since then, DMAC stock has decreased by 44.5% and is now trading at $2.07. View the best growth stocks for 2022 here. When is DiaMedica Therapeutics' next earnings date? DiaMedica Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 10th 2022. View our earnings forecast for DiaMedica Therapeutics. How were DiaMedica Therapeutics' earnings last quarter? DiaMedica Therapeutics Inc. (NASDAQ:DMAC) released its earnings results on Wednesday, May, 4th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.20) by $0.07. During the same quarter in the prior year, the company posted ($0.19) EPS. View DiaMedica Therapeutics' earnings history. Who are DiaMedica Therapeutics' key executives? DiaMedica Therapeutics' management team includes the following people: Mr. Dietrich John Pauls MBA, Pres, CEO & Director (Age 51, Pay $684.09k) (LinkedIn Profile)Mr. Scott B. Kellen C.A., CFO & Company Sec. (Age 57, Pay $391.72k)Dr. Harry W. Alcorn Jr., Pharm.D., Sr. VP of Clinical Operations (Age 66, Pay $390.27k) (LinkedIn Profile)Dr. Edward G. Calamai Ph.D., Consulting Head of ManufacturingDr. Kirsten L. Gruis M.D., M.S., Chief Medical Officer (Age 49)Mr. Dominic R. Cundari, Chief Commercial Officer (Age 71) Who are some of DiaMedica Therapeutics' key competitors? Some companies that are related to DiaMedica Therapeutics include Viking Therapeutics (VKTX), Rhythm Pharmaceuticals (RYTM), Rigel Pharmaceuticals (RIGL), Impel Pharmaceuticals (IMPL), Nature's Sunshine Products (NATR), Verastem (VSTM), VBI Vaccines (VBIV), Zomedica (ZOM), Selecta Biosciences (SELB), Fulcrum Therapeutics (FULC), Theratechnologies (THTX), ProPhase Labs (PRPH), Kamada (KMDA), Wave Life Sciences (WVE) and Pardes Biosciences (PRDS). View all of DMAC's competitors. What other stocks do shareholders of DiaMedica Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other DiaMedica Therapeutics investors own include VBI Vaccines (VBIV), Inovio Pharmaceuticals (INO), Dynavax Technologies (DVAX), Pfizer (PFE), Vaxart (VXRT), Aldeyra Therapeutics (ALDX), Capricor Therapeutics (CAPR), Oncolytics Biotech (ONCY), Sesen Bio (SESN) and Sorrento Therapeutics (SRNE). When did DiaMedica Therapeutics IPO? (DMAC) raised $18 million in an initial public offering (IPO) on Friday, December 7th 2018. The company issued 4,000,000 shares at $4.00-$5.00 per share. Craig-Hallum Capital Group served as the underwriter for the IPO. What is DiaMedica Therapeutics' stock symbol? DiaMedica Therapeutics trades on the NASDAQ under the ticker symbol "DMAC." How do I buy shares of DiaMedica Therapeutics? Shares of DMAC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is DiaMedica Therapeutics' stock price today? One share of DMAC stock can currently be purchased for approximately $2.07. How much money does DiaMedica Therapeutics make? DiaMedica Therapeutics (NASDAQ:DMAC) has a market capitalization of $54.74 million. The company earns $-13.59 million in net income (profit) each year or ($0.58) on an earnings per share basis. How many employees does DiaMedica Therapeutics have? DiaMedica Therapeutics employs 14 workers across the globe. How can I contact DiaMedica Therapeutics? DiaMedica Therapeutics' mailing address is 2 CARLSON PARKWAY SUITE 260, MINNEAPOLIS MN, 55447. The official website for DiaMedica Therapeutics is www.diamedica.com. The company can be reached via phone at (763) 312-6755 or via email at skellen@diamedica.com. This page (NASDAQ:DMAC) was last updated on 7/2/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
